share_log

Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Point72 Asset Management, L.P.(0.2%),Point72 Capital Advisors, Inc.(0.2%), etc.

Arcutis Biotherapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Point72 Asset Management, L.P.(0.2%),Point72 Capital Advisors, Inc.(0.2%), etc.

Arcutis Biotherapeutics | SC 13G/A：超過5%持股股東披露文件(修正)-Point72 Asset Management, L.P.(0.2%),Point72 Capital Advisors, Inc.(0.2%)等
美股SEC公告 ·  11/15 08:57

Moomoo AI 已提取核心訊息

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, was the subject of a Schedule 13G/A filing with the Securities and Exchange Commission (SEC) on September 30, 2024, indicating a change in ownership by several related investment entities. Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., Cubist Systematic Strategies, LLC, and Steven A. Cohen collectively reported shared voting and dispositive power over 247,055 shares of Arcutis Biotherapeutics, representing 0.2% of the company's class of common stock. The filing, signed by authorized person Jason M. Colombo, clarifies that none of the reporting persons directly own shares but have investment and voting power through managed funds. The address for Point72 Asset Management, Point72 Capital Advisors, and Mr. Cohen is in Stamford, CT, while Cubist Systematic Strategies is located in New York, NY. All entities are organized under Delaware law, with Mr. Cohen being a U.S. citizen. The filing also indicates that the reporting persons do not have an intention to change or influence the control of Arcutis Biotherapeutics.
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, was the subject of a Schedule 13G/A filing with the Securities and Exchange Commission (SEC) on September 30, 2024, indicating a change in ownership by several related investment entities. Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., Cubist Systematic Strategies, LLC, and Steven A. Cohen collectively reported shared voting and dispositive power over 247,055 shares of Arcutis Biotherapeutics, representing 0.2% of the company's class of common stock. The filing, signed by authorized person Jason M. Colombo, clarifies that none of the reporting persons directly own shares but have investment and voting power through managed funds. The address for Point72 Asset Management, Point72 Capital Advisors, and Mr. Cohen is in Stamford, CT, while Cubist Systematic Strategies is located in New York, NY. All entities are organized under Delaware law, with Mr. Cohen being a U.S. citizen. The filing also indicates that the reporting persons do not have an intention to change or influence the control of Arcutis Biotherapeutics.
Arcutis生物製藥公司是一家生物製藥公司，2024年9月30日與證券交易委員會（SEC）進行了13G/A表格申報，表明幾個相關投資實體對公司所有權發生了變化。Point72資產管理公司，Point72資本顧問公司，立方體系統性策略有限責任公司和Steven A. Cohen共同報告對Arcutis生物製藥公司247,055股股票擁有共同的投票和處置權，佔公司普通股類別的0.2%。由授權人Jason M. Colombo簽署的申報澄清，報告人中沒有任何人直接持有股份，而是通過管理基金擁有投資和投票權。Point72資產管理，Point72資本顧問和Cohen先生的地址在康涅狄格州斯坦福市，而立方體系統性策略位於紐約市。所有實體均根據特拉華州法律組建，Cohen先生是美國公民。申報還指出，報告人沒有意圖改變或影響Arcutis生物製藥公司的控制權。
Arcutis生物製藥公司是一家生物製藥公司，2024年9月30日與證券交易委員會（SEC）進行了13G/A表格申報，表明幾個相關投資實體對公司所有權發生了變化。Point72資產管理公司，Point72資本顧問公司，立方體系統性策略有限責任公司和Steven A. Cohen共同報告對Arcutis生物製藥公司247,055股股票擁有共同的投票和處置權，佔公司普通股類別的0.2%。由授權人Jason M. Colombo簽署的申報澄清，報告人中沒有任何人直接持有股份，而是通過管理基金擁有投資和投票權。Point72資產管理，Point72資本顧問和Cohen先生的地址在康涅狄格州斯坦福市，而立方體系統性策略位於紐約市。所有實體均根據特拉華州法律組建，Cohen先生是美國公民。申報還指出，報告人沒有意圖改變或影響Arcutis生物製藥公司的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間